- Home
- GDHG vs BLRX Comparison
GDHG vs BLRX Comparison
Compare GDHG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- BLRX
- Stock Information
- Founded
- GDHG 2008
- BLRX 2003
- Country
- GDHG China
- BLRX Israel
- Employees
- GDHG N/A
- BLRX N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- BLRX Health Care
- Exchange
- GDHG Nasdaq
- BLRX Nasdaq
- Market Cap
- GDHG 19.4M
- BLRX 17.1M
- IPO Year
- GDHG 2023
- BLRX 2011
- Fundamental
- Price
- GDHG $4.28
- BLRX $3.46
- Analyst Decision
- GDHG
- BLRX Strong Buy
- Analyst Count
- GDHG 0
- BLRX 2
- Target Price
- GDHG N/A
- BLRX $19.00
- AVG Volume (30 Days)
- GDHG 53.3K
- BLRX 23.1K
- Earning Date
- GDHG 07-11-2025
- BLRX 11-20-2025
- Dividend Yield
- GDHG N/A
- BLRX N/A
- EPS Growth
- GDHG N/A
- BLRX N/A
- EPS
- GDHG N/A
- BLRX N/A
- Revenue
- GDHG $16,666,899.00
- BLRX $17,251,000.00
- Revenue This Year
- GDHG N/A
- BLRX N/A
- Revenue Next Year
- GDHG N/A
- BLRX N/A
- P/E Ratio
- GDHG N/A
- BLRX N/A
- Revenue Growth
- GDHG N/A
- BLRX 1.19
- 52 Week Low
- GDHG $2.40
- BLRX $2.30
- 52 Week High
- GDHG $1,968.41
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- GDHG 40.65
- BLRX 43.97
- Support Level
- GDHG $3.96
- BLRX $3.10
- Resistance Level
- GDHG $4.25
- BLRX $3.52
- Average True Range (ATR)
- GDHG 0.28
- BLRX 0.21
- MACD
- GDHG 0.07
- BLRX -0.00
- Stochastic Oscillator
- GDHG 50.31
- BLRX 43.04
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.